Suzhou Sepax Technologies (688758.SH) achieved a net profit of 85.16 million yuan in 2024, representing a year-on-year increase of 62.25%.

Suzhou Sepax Technologies (688758.SH) released its performance report for the year 2024, with a total operating income of 315 million yuan, a year-on-year increase of 28.65%; net profit attributable to owners of the parent company was 85.16 million yuan, a year-on-year increase of 62.25%; net profit attributable to owners of the parent company after deducting non-recurring gains and losses was 77.8451 million yuan, a year-on-year increase of 69.15%; basic earnings per share were 0.2324 yuan. During the reporting period, the company continuously expanded its market, successfully introducing the industrial purification medium supply chain to multiple new customers. In addition, the company focused on maintaining existing customers, following up on projects already introduced and actively exploring new projects to encourage repeat business from existing customers. As the company continues to increase its clinical and commercial projects in key biopharmaceutical areas such as antibodies, insulin/GLP-1, and recombinant proteins, the business scale further expands, and profitability continues to improve.